Search Results

Tretinoin

Tretinoin is an FDA-approved drug that is used to induce remission in patients who have acute promyelocytic leukemia (APL, also known as "M3 AML"), a type of acute myeloid leukemia (AML), with the t(15;17) translocation and/or the presence of the PML-RARa gene and who are intolerant of, refractory to, or have relapsed from anthracycline-based chemotherapy.

211Astatine-CD123 Radioimmunotherapy for Cancer (Stem) Cell-Directed Treatment of Acute Leukemia

Because acute leukemias are very sensitive to radiation, radioisotopes are ideal payloads to arm antibodies against these difficult-to-cure, aggressive blood cancers. Here, we will develop fully human anti-CD123 antibodies carrying the highly potent alpha-emitter astatine-211 (211At) as a new therapy for acute leukemia.

Bold goal, bold action

As we observe World Cancer Day, I’m reflecting on my own family’s experience with blood cancer, the children with blood cancer I have had the honor of knowing, and the many individuals and families who have been impacted by a blood cancer diagnosis.

Our work at The Leukemia & Lymphoma Society (LLS) has had a positive impact on so many, but we can do even more to accelerate progress for the blood cancer patients we serve.

Niclosamide for the Treatment of Relapsed/Refractory Pediatric Acute Myeloid Leukemia

Niclosamide is an FDA approved anti-parasitic drug that is well tolerated and acts synergistically with chemotherapy to kill AML cells. We will conduct a Phase I clinical trial with niclosamide in combination with cytarabine for children with relapsed/refractory pediatric AML. ShRNA/CRISPR screens demonstrated that Bcl-2 is upregulated in niclosamide resistant cells. We will study the effects of the Bcl-2 inhibitor venetoclax in combination with niclosamide in pediatric AML.

Treatment Advancements for Acute Lymphoblastic Leukemia (ALL) in Children and Adults

In the Face of Uncertainty in Washington, The Leukemia & Lymphoma Society Stands with Patients

The Leukemia & Lymphoma Society Welcomes Five Members to Board of Directors

Therapeutic exploitation of novel mouse models and metabolic interventions in leukemia

Our research program aims to gain a deeper understanding of the pathobiology of T-ALL and HSTL. To this end, we will use novel mouse models, cutting-edge techniques and comprehensive genetic, pharmacological and metabolic interventions. In addition, we will perform unbiased experiments to identify novel therapeutic targets. Our goal is to uncover new tools and targets for the treatment of T-ALL and HSTL, which could be used for the benefit of patients in the short/mid-term.

Cancer Survivorship in Young Adults: Acute Lymphoblastic Leukemia (ALL)

The Leukemia & Lymphoma Society Expands Information Resource Center Hours

Enterome Selected to The Leukemia & Lymphoma Society’s Therapy Acceleration Program

Leukemia & Lymphoma Society Board of Trustees, Southern Florida Chapter

The Leukemia & Lymphoma Society Applauds Therapy Advances for Myeloma Patients

Chronic Lymphocytic Leukemia (CLL): What Are My Treatment Options?

Chronic Lymphocytic Leukemia (CLL): What Are My Treatment Options?

UFCW AND THE LEUKEMIA & LYMPHOMA SOCIETY ARE UNITED IN THE FIGHT TO END CANCER

FDA Approves Vyxeos for Secondary Acute Myeloid Leukemia in Children

Targeting the interaction of leukemia stem cells with their niche to treat myelofibrosis

Bone marrow scar formation (fibrosis) is a hallmark of myelofibrosis and contributes significantly to the disease progression. We use mouse genetics to model myelofibrosis and understand the cellular and molecular makeup of the diseased microenvironment. We aim to understand the composition and alteration of the bone marrow microenvironment in myelofibrosis. This may provide novel therapeutic targets for myelofibrosis.

Cotargeting oncogenic protein translation and apoptosis in acute myeloid leukemia

The focus of my research is to evaluate the efficacy of and to unravel the molecular mechanisms underpinning a novel drug combination in AML targeting oncogenic protein translation and apoptosis. We will utilize genetic perturbation and other orthogonal approaches, including in vitro and ex vivo assays, and in vivo AML PDX models. The goal of my research is to transform the clinical management of AML patients, particularly for relapsed and difficult-to-treat subgroups.

The Leukemia & Lymphoma Society Announces Reimagined Executive Leadership Team

Oral Formulation of Methotrexate Now Available for Children with Leukemia Subtype

FDA Approves New Treatment for Adults with Chronic Myeloid Leukemia

Chronic Myeloid Leukemia: Diagnosis, Treatment, and Side Effect Management

Chronic Lymphocytic Leukemia: Diagnosis, Treatment, and Side Effect Management

Key Insights: Treating Adult Acute Lymphoblastic Leukemia (ALL)